Institute of Pharmacy and Molecular Biotechnology, Department of Pharmaceutical Technology and Biopharmacy, University of Heidelberg, Germany.
Int J Pharm. 2011 Aug 30;415(1-2):150-7. doi: 10.1016/j.ijpharm.2011.05.066. Epub 2011 Jun 2.
The aim of this study is to improve of oral peptide delivery by a novel type of liposomes containing tetraether lipids (TELs) derived from archaea bacteria. Liposomes were used for the oral delivery of the somatostatin analogue octreotide. TELs were extracted from Sulfolobus acidocaldarius and subsequently purified to single compounds. Liposomes were prepared by the film method followed by extrusion. Vesicles in size between 130 and 207 nm were obtained as confirmed by photon correlation spectroscopy. The pharmacokinetics of radiolabeled TELs in liposomes was investigated after oral administration to rats. 1.6% of the applied radioactivity in fed and 1.5% in fasted rats was recovered in the blood and inner organs after 2h, while most of the radioactivity remained in the gastro-intestinal tract. After 24h the percentage of radioactivity in inner organs was reduced to 0.6% in fed rats, respectively 1.0% in fasted animals. Several liposomal formulations containing dipalmitoyl phosphatidylcholine (DPPC) and TELs in different ratios were loaded with octreotide and orally administered. Liposomes with 25% TEL could improve the oral bioavailability of octreotide 4.1-fold and one formulation with a cationic TEL derivative 4.6-fold. TEL-liposomes probably act by protecting the peptide in the gastro-intestinal tract.
本研究旨在通过新型脂质体来改善口服肽类药物的传递,这种脂质体含有源自古细菌的四醚脂(TEL)。脂质体被用于奥曲肽类似物的口服传递。TEL 从 Sulfolobus acidocaldarius 中提取,随后经过纯化得到单一化合物。脂质体通过薄膜法制备,然后进行挤压。光子相关光谱学证实,得到的囊泡粒径在 130 至 207nm 之间。通过放射性标记 TEL 脂质体口服给予大鼠,研究了其药代动力学。在给予饲料和禁食的大鼠 2 小时后,血液和内脏中回收的放射性活性分别为 1.6%和 1.5%,而大部分放射性活性仍留在胃肠道中。24 小时后,在给予饲料的大鼠中,放射性活性在内脏中的百分比降至 0.6%,而在禁食动物中则降至 1.0%。几种含有二棕榈酰磷脂酰胆碱(DPPC)和不同比例 TEL 的脂质体被加载奥曲肽并口服给予。含有 25%TEL 的脂质体可使奥曲肽的口服生物利用度提高 4.1 倍,而一种含有阳离子 TEL 衍生物的制剂可提高 4.6 倍。TEL 脂质体可能通过在胃肠道中保护肽来发挥作用。